DEBRA BN BO LSRHER Cine 2RBRmCRR WALZ SRA 1 SBS (ERTA(GLP-1 RAs) aS 2015478 16H » HAMastuda UZ; 201547101 30H > feBNauck #2; 2015411 13 eelSchuster BGS > ARRAN Ma FET ABaL UIMUSGLP-RAs + 3Xe7GLP-RAstE2 20 ROR TR fats ROR i ° PEK SENauck BARA FE BR (Incretin) Wifi’ OS > PPAR (RS > RSE BL ES A AR abe SRAMESM RAAT #-HAttTBAUk AM 2 TUBER > BSS Tia BL FEVER > — 8 By HE A SESH at BN BASE © TEFE BEM RAM Re Fronzo8pe 0 A 2 AUR ERY es SE, wi» BBE BELBU > BBR be SRP Dik > APRS 4 ROE + BE KES CIncretin) QW FMR FESS + DEIR oe AN Md Wt BH SS (Glucago) Sinn + BRNGaHRSHON + FETE RTA ANY BHO BUI SED BES Fa BE EBC TT PRLS SCH SU0 5 [EOS + GLP-1 (3RFHESRBA-1 ) FBT A 89 Be He ESE Ce BE Hi ARE UIE RASC IP CH SAK DMMB gastric inhibitory StI A glucose-dependent insulinotropic polypeptide) KGLP-1 (glucagon like peptide-1) + (E2800 FRA Act > BYR BSR EAR Cincretin effect) (HRA AKILAY » ERT EF BRR » TOPE FAAS) kes 6 A BELES BCIBE IS 3 ) ARRAS EA » FechG Pease BRAVE + iNiGLP-1BRREVIAE > HY A IL Pe EA REE EA Je SE Pt RABIN AE GLP- 1 7s « GLP- 1 HH Bas AR > RSEAS-4 CDPP-4) SERRATE RACE + PROG» AAR mi > (i) lik 76s 2 3S eS HS GLP-LLZ FF ° CL) DPP-ad Ne > ASEBAT polypeptide »© ‘BIDPP-4.2. (FAS, BEAEALRECLP-19 A RRIES ie ° (2)CLP-1 81 > FOSS BUS EAA A HERIGLP-1 > {AA RDPP- ALT HE BEEP GLP-1 ZB RE FTES ° GERESCERAY HRBAICEGLP- LAE (GLP 152 (ee) > GLP-172{FFR GLP 1 EBS i Sed ig] a Be a Bik ABBAS LANGA Ws ° AE SEE ALARM P A ZR AY 6 RUMYGLP-1 S20 fe A > Zee iL BEEF RU 6 ANSTO AN WF BE > TERME FE > ETT) YG NS Be aE SES HE 28 SE 38 + SPO TLUSDERA (Blood-Brain Barrier) , #8 ARM i0 fe ita op ty WUD EERE > ERE « EI) GLP-1 RAsZDA MEPAGLP-1 RAs (EAI SM PUWRPEZGLP-1 + (ERR E (heterogeneity) ° @#S0877 AAAS TSE > A) > PERSIE El. By DHS BAAR REBNYAE II > AR SETAY Cdosing interval) , MERMbImn eset Re. PROBE fe SAR TA > BE He Sri] © APBUGLP-1 RAS#RU LL exendin-4 2% SE REBEL AHEGLP - 1 hy TERE « exendin-4 yee EE WER AR» HE 5 3% 30 ‘SREBEGTET JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2016. vol. 24, No.1 HEWAABECLP-1 > ASEDPP-453 HE > ALBEE MIRSGLP-15248 ° 20] = SCE HAC FSS FB SB ‘LUBED ZAS IND = » FA RA Re EA C Shor t- acting prandial compounds) » Hlexenat ideKLixisenatide + SEU] AEE I BRE © . RAGE AERA Clong- acting nonprandial compounds ) iillexenatidedext {EADS + liraglutide > albiglutide » Dulaglutide > # ET 1 PW SS De ST 3€ (glucagon) FAZER MBE {BERZIE (Be) GLP-RASHIAR BOLNauckMRBAR— HRA ESCH ° DAWES Pe BERET HE SOSF Be BPA Bi FF EE (Increatin-based therapies rwhere will we be 50 year from now?) . SCPHEHMGLP-1 RAs i8iFA fA. GHEE) AAUP OAU RE RR BRIE (Liraglutide 3mg > FDACGS8 ) + TEAR ER BRAY Ae: UBS» BERT > JRVSRECERRMGIFIS (NAFLD) + JE WEA TENRWGTEHF AR (NASH) + BBE YESUSUIE REY (polycystic ovary syndrome) ° ARN BRIM AE ~ERA ERD — BGR SEL FATS i ESE Ab PERI > AP Be ae (psoriasis) + LA (coronary heart disease) © fe ot BU fe Ge LE i AY Dulaglutide » FaimxtSta8 » Agvet: SY 2O9STGR > PEAR EREN/) > —BBFT—2R > ASPIRE Be > Le 8 WH PERRIS CRE > Fi GR > BoA BEG » AURA TT BR ORY Gl As + 7848 TBE CA BTA # Cee —Mphase 2EF ER) , FRAMES ROY, IADB BETTE ° Ri GLP-LSHSE RO] > BEETLE FOS Bc BURR > TRF SLD BFL BES HEE > MRR ROR Wo AMAT > CAEL > PRL... SE) BHR 7 | ES MHHAS EER GLP-1 RAs BTS] 2 6 NAL + Zee BRN se Ben AEA TAY 6 ANAL + BEA EER B ANN TRS HEC BOA © BREA CRMBETRIA ANY 8 AIM > TEBE jANUHERSE ° AAUGLP-1 RAs fy HRERABR RAY (— HI A) > BAUR T BME APE + 7E2 80 9H RIG» GLP-1 2H SOC Pi) SS HE BR ME EF BEN Pe tl © SE (EA a a a A 31 SHER Cl BORER ZN > PRT (biphasic) PRES KCHE > REMITE BETTS > BUR ATEEZE > 1B TETRA TEMS TRIN + DHE Hi BRS» DAT BY RS proinsulin) Z EMA + BRAINS » ASEH fe 8 AMI A TE BARGE + ATHY 6 AM A at (mass) ° Schus ter BGR IMB te Bis E TMV AEDeg Lut def HHHSL > ‘CREA IAGLP- 1 REE A G (igG) MA > BRERA Wate > PSSST B9O// EF + TPES PBR BD FIR > Alt Hy — BBE —2 © GEAWARD 138 AWARD 6 ZUPZE > WEIUERAYAEIB8 LiraglutidesH) » 4ei> HEA vii fd—R—Kiexenat idetHtl + tele PESIPERAFIAIGE | i raglutides—Se HH —-2kiexenat idetHth ° Mat suda#t#2d8 ti A ABER JEMODPP—-4A AN AC REDRSEM (sulfonylureas) »° 40) SARTHGAR > CLP-1 SZABO & Fi HAT REEA TH) HEM Rme t forming hs CLUE RTARIN RSE SSR 1, BUSS + SEL EH IGE SE, SFP BES AK 1 SH© ‘BEET@ESS JOURNAL OF KAOHSIUNG MEDICAL ASS( CIATION 2016. vol. 24 Intestinal Raed nee Gip-1 | s-FAE% GLP-1 Bhi Release . GLP-1(7-36) ite Activ DPP 4 pi] —»C PPP inababi pik £16 tivation BRA | 0% of Pool) 1 GLP-1(9-36) sRie HE DPP=dipeptidyl peptidase(— kA) jucagon-like peptide( 37} #88iiK) (GLP-1 Receptor Agonist) PURE Rev Endocrinol 2012;8:728-742. SRG PTAESS : PAE RLO34F1 Fi 20 4. Jennifer M. Trujillo: H Wesley Nuffer: GLP-1 Receptor 2.Debbie A Hinnen : Agonists for Type 2 Diabetes Therapecctic options for the Mellitus :Recent Pevelopments Management of Postprandial and Emerging Agents. Glucose in Patients with Type Pharmacotherapy 2014;34:1174- 2 Diabetes on Basal insulin . 1186. Clinical Diabetes 201 175- 5. Juris J.Meier. Michael 180. A. Nuck: Incretin-based 3.Juris J. Meier:GLP-1 therapie: Where will we be 50 receptor agonists for years from now? Diabetolcgia. individualized treatment of 2015;58:1745-1750. Type 2 diabetes mellitus. J NatMERLE (GLP-1 RAs) S Cont) Troma Troe Cam) > OD [LSS GLP-1 \caplneeenen: z Llib sma La at CF) Damne Tk rad (aval) ‘Te arse La ie i apt = :GLP-1 4 RASA He RZ He A GLP-1 BAR AE BRR SR SO PRS > iia BAR He A PSAP BE AL) GLP-1 Sst 4 34 #4] ALF 13S Sh sR AK (peptide) HEM GLP] RHR E A A GLP-1 RA a $8 S238 BE Hunan GLP=1 based Extendin-4 based (LAGE GLP-1 Rat) eeextendin-4 AAR -EMHK ROK Rok AIbiglutide | [TLiragiutide | —2##—* Kak (Tanzeum) Wictoza) Exenatide Exenatide Ce FE th 2) (Byetta) Dulaglutide (ydureon) (Trulicitv) Lixisenatide Senaglutide =. GLP-12 4738 33S MEBSEMSESE JOURNAL OF KAOHSIUNG MEDICAL ASSOCIAT] Be ABARAT AE AK] HEAR KAY PLR (ON 2016. vol. 24, No.1 BR 4a 2GLP-1RA Fe 2kGLP-1RA ARITA A ARLE ARAR RAR) RST ER] SEAR a A Hey Exenatide , Lixisenatide /Albigutide, Dulaqlutide |Exenatide LAR, Liraqlutide + RH (half-life) —[2~5-)a% 12). 8F BBR Wt Fi (effects) SM so $8 1B LS Ak ik 8 Bik ik 8) SABRI Pe Lek FE BUR By Hy oe |e ik A a ETE ia Hl beh) ak a ii kak BE a. aD PS ME AB AS do PSR (0-2/4) (2-5/4) Ff 2ESa 20-40% iB SB AE AB A) |ABAR BS (428 BH)